November 4, 2011 – PhysioSonics announced that it received a $2.5 million grant from the Telemedicine and Advanced Technology Research Center (TATRC). TATRC is an organization within the headquarters of the U.S. Army Medical Research and Materiel Command, located at Fort Detrick, Maryland. With this grant, PhysioSonics will optimize its proprietary cerebral blood-flow monitor to detect vasospasm. Following a successful launch in the civilian healthcare market, the military will test the blood-flow monitor with the goal of deploying it at military facilities that care for soldiers with traumatic brain injuries (TBI).

November 4, 2011 – W. L. Gore & Associates announced that Royal Sussex County Hospital in Brighton, United Kingdom, is the first medical center in the United Kingdom to enroll a patient in the Gore REDUCE clinical study. The study is a U.S. Food and Drug Administration (FDA)-approved prospective, randomized, multi-center, international trial designed to demonstrate safety and effectiveness of the Gore HELEX septal occluder for patent foramen ovale (PFO) closure in patients with a history of cryptogenic stroke or imaging-confirmed transient ischemic attack (TIA). The unique study includes up to fifty investigational sites in the United States and Europe. This patient enrollment was achieved by the site’s study investigator, David Hildick-Smith, M.D., director of cardiac research unit, Brighton and Sussex University Hospitals.

November 3, 2011 – Lantheus Medical Imaging announced important changes to the U.S. product label for Definity Vial for (perflutren lipid microsphere) Injectable Suspension. The contrast agent is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

November 1, 2011 – CardioComm Solutions, a provider of hardware and software solutions for cardiovascular health management, announced the extension of their current OEM agreement with GE Healthcare. The agreement renewal means both companies will continue to play a role in the expanding cardiovascular monitoring and diagnostic devices segment, forecast recently by MarketResearch.com to grow a compound annual growth rate (CAGR) of 5 percent between now and 2017.

November 1, 2011 – Claret Medical Inc. said its Montage System has received CE mark approval as the world's first complete system of filtration to protect both carotid arteries simultaneously. The 6 French catheter is delivered via radial or brachial access, providing complete neuro protection during intravascular procedures such as transcatheter aortic valve intervention (TAVI). The unique design of the Montage System not only provides neuro-protection from debris, but also captures and removes potential stroke-causing embolic material from the body.